Medication info
Pioglitazone 15/850 mg Tablet (Pioglitazone Hydrochloride, Metformin Hydrochloride)

Pioglitazone 15/850 mg Tablet (Pioglitazone Hydrochloride, Metformin Hydrochloride)

Prescription medicationTablet
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Dalim Biotech Co., Ltd.
Appearance
White to grayish-white rectangular film-coated tablet
Packaging
30 tablets (10 tablets/PTP*3)
Approval status
Active

MFDS item code 201705701 · Approved 2017.07.17 · Insurance code 664602200

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine per day, assess the adequacy of the treatment response, and gradually adjust the dose. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their existing doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching patients from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, the dose should not be increased to the maximum dose of this medicine in elderly, debilitated, or malnourished patients. After administration of this medicine to a patient, or after a dose increase, the patient must be carefully monitored for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which can reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG does not worsen, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Ingredients

Manufacturer
Dalim Biotech Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medicine helps improve blood sugar control when used together with dietary control and exercise in patients with Type 2 diabetes. The components of pioglitazone and metformin work together to assist in improving blood sugar levels, thereby aiding in diabetes management. Regular use enhances blood sugar control for maintaining a healthy life.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine per day, assess the adequacy of the treatment response, and gradually adjust the dose. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their existing doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching patients from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, the dose should not be increased to the maximum dose of this medicine in elderly, debilitated, or malnourished patients. After administration of this medicine to a patient, or after a dose increase, the patient must be carefully monitored for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which can reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG does not worsen, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Precautions

This medicine contains two active ingredients, each of which has different precautions to keep in mind. First, one ingredient may cause a rare side effect known as lactic acidosis, which occurs when too much lactic acid builds up in the body and can be life-threatening if severe. The risk is higher in patients with impaired kidney function or those with poor health due to heart disease, infections, etc. Therefore, if symptoms such as dehydration, difficulty breathing, muscle pain, or fatigue occur while taking this medication, immediate consultation with a physician is necessary. Additionally, it is advisable to avoid using this medicine in patients with impaired liver function, and excessive alcohol consumption should be avoided. This medication should be monitored regularly in conjunction with liver and kidney function tests, and extra caution is required in the elderly or those with compromised kidney function. The other ingredient may put stress on the heart and should not be used in patients with heart failure. Use of this medication can lead to fluid retention, resulting in edema or worsening heart failure symptoms, so symptoms such as weight changes, difficulty breathing, and leg swelling should be closely monitored. If any of these symptoms appear, consultation with a physician regarding medication adjustment or discontinuation should be considered. This medicine should not be administered to patients with a history of bladder cancer or those with active bladder cancer. If symptoms such as hematuria, urinary difficulties, or urgency arise during treatment, immediate notification of healthcare personnel is required. Women who are pregnant or nursing should not take this medication, and safety in pediatric patients has not been established. Also, this medicine may interact with other medications, so it is essential to inform your doctor or pharmacist of any other drugs being taken. Special care should be taken when used in conjunction with drugs that affect kidney function. While taking this medication, regular monitoring of blood sugar, blood tests, and kidney and liver function tests is important, and immediate consultation with healthcare personnel is essential if any abnormal symptoms occur. Finally, this medicine may cause hypoglycemia, so it is necessary to avoid skipping meals, excessive exercise, and alcohol consumption, and to respond promptly if hypoglycemic symptoms occur.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • asthenia
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 34 more
  • congestive heart failure
  • excessive and rapid weight changes
  • edema
  • upper respiratory tract infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower limb edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • decreased vision
  • diabetic macular edema
  • liver failure
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • intragastric air retention
  • increased serum creatinine
  • increased serum urea
  • fracture
  • urinary disorders
  • urgency

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to protect it from air and moisture, and it is important to maintain a storage temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the efficacy and safety of the medication.

Appearance and packaging

Appearance

White to grayish-white rectangular film-coated tablet

Package unit

30 tablets (10 tablets/PTP*3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.